Virginia Devonshire

Virginia Devonshire

Auto-generated profile, based on publicly available information

Virginia Devonshire

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2018 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
VDVirginia Devonshire
Virginia Devonshire
RPRichard Phillips
Richard Phillips
HWHilary Wass
Hilary Wass
GRGerald Da Roza
Gerald Da Roza
PSPeter Senior
Peter Senior
Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved in more than 65 countries for the treatment of relapsing–remitting multiple sclerosis (RRMS). Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease activity and the rate of brain volume loss, and improved disability outcomes in patients with active RRMS who were either treatment naive (CARE-MS I study) or who had an inadequate response (≥ 1 relapse after ≥ 6 months of treatment) to prior therapy (CARE-MS II study). Adverse events (AEs) associated with alemtuzumab include infusion-associated reactions, infections, and autoimmunity. The most commonly reported autoimmune AEs observed with alemtuzumab involve the thyroid gland, followed by immune thrombocytopenia and nephropathies. A monitoring program was designed and implemented to facilitate the early detection of autoimmune events to ensure timely and adequate management. The aim of this article is to provide physicians (including neurologists, general practitioners, endocrinologists, hematologists, and nephrologists who may be less familiar with the symptoms and treatment of autoimmune events), with practical real-world recommendations for the monitoring and management of autoimmunity associated with alemtuzumab treatment.

30 April 2010 in BMC Neurology
Verified
Journal Article
Open access
PDF file
VDVirginia Devonshire
Virginia Devonshire
TATxomin Arbizu
Txomin Arbizu
BBBjörn Borre
Björn Borre
MLMichael Lang
Michael Lang
ALAlessandra Lugaresi
Alessandra Lugaresi
PCPeter Cornelisse
Peter Cornelisse
Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with self-injection and could, therefore, improve treatment adherence. This study was performed to assess the suitability of a new electronic device for the subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS.

25 October 2011 in Therapeutic Delivery
Verified
Journal Article
Closed access
VDVirginia A Devonshire
Virginia A Devonshire
ECElisabetta Verdun di Cantogno
Elisabetta Verdun di Cantogno
Multiple sclerosis is a chronic disease requiring lifelong treatment with disease-modifying drugs that aim to prevent relapses and slow the progression of disability. The established first-line tre...

8 March 2016 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
VDVirginia A. Devonshire
Virginia A. Devonshire
AFAnthony Feinstein
Anthony Feinstein
PMPatrick Moriarty
Patrick Moriarty
In a multicentre, single-arm, observational, phase IV study, we evaluated 24-week treatment adherence of relapsing multiple sclerosis (RMS) patients using an electronic auto-injection device (RebiSmart®) for subcutaneous injection of interferon (IFN) β-1a. A total of 162 adult participants with RMS were enrolled into the study to use RebiSmart® to self-administer IFN β-1a 44 μg three times weekly for a maximum of 96 weeks. The number of administered injections was recorded in the electronic device log. Adherence to treatment was defined as the administration of ≥80 % of expected injections. Cognitive impairment and injection anxiety were assessed via questionnaires. Overall, 91.8 and 82.9 % of participants were adherent to treatment at weeks 12 and 24, respectively. By weeks 12 and 24, 8.2 and 13.9 % of participants had discontinued treatment. There were no statistically significant differences in adherence rates at weeks 12 and 24 according to cognitive impairment status or injection anxiety. By week 24, 69.9 % of participants were less fearful of injection than when they started the study. According to participant evaluations, the absence of a visible needle, comfort settings, and the calendar for tracking the injection schedule were all important features of the RebiSmart® injection system. At week 24, 99.3 % of participants reported that they would like to continue using RebiSmart® as their injector. RebiSmart® use is associated with high treatment adherence, as objectively assessed using electronic injection logs. Future research should examine if RebiSmart® use improves long-term treatment outcomes in RMS. This study was registered with ClinicalTrials.gov as NCT01128075, on May 20, 2010.